Adapalene Benzoyl Peroxide Acne Scarring: New Study Demonstrates Efficacy in Preventing Acne Vulgaris Damage

Adapalene Benzoyl Peroxide Acne Scarring : A study led by Nobukazu Hayashi from Toranomon Hospital in Tokyo found that ADP/BPO gel and BPO gel effectively prevent scarring in adults with acne. The study found that the ADP/BPO and BPO groups had higher success rates compared to the control group, which was only 47.4% successful. 3D analysis showed improved atrophic scarring rates in both groups after 24 weeks. The study found minor drug side effects in the ADP/BPO group but none in the BPO group. From Aug. 2020 to Sept. 2021, the study was conducted at 13 medical centers in Japan. There were 120 people aged 20 and up in the survey. They were divided into three groups: 40 in ADP/BPO, 44 in BPO, and 42 in control. An EDC device and minimization method were used to ensure equal group sizes.

Adapalene Benzoyl Peroxide Acne Scarring

Also Read: EMA Updates Topiramate Guidance: for Medication Use

ADP/BPO and BPO gels effectively reduce inflammatory lesions to 10 or less. Compared to the control arm, the high success rates in both treatment groups were statistically significant (P=0.0006 for both). The rate of change in atrophic scarring improved significantly over the study period (P=0.0004 and P0.0001, respectively). Although most people in the ADP/BPO group tolerated the medicines well, 7.5% experienced mild side effects. No reports of bad effects in the BPO arm. This study builds on previous research showing ADP/BPO gel’s effectiveness in reducing atrophic scarring risk and severity over six months. Hayashi and his team aimed to address knowledge gaps regarding the effects of ADP/BPO and BPO gels on atrophic scarring in acne vulgaris maintenance treatment.

The results suggest that ADP/BPO and BPO gels can help prevent the return of inflammatory lesions in people with acne vulgaris. It was found that the procedure reduced atrophic scars without worsening them. The study is a crucial starting point for further research on long-term treatments for acne and atrophic scars. Study participants had 10-100 atrophic scars ≥0.5 mm in diameter and fewer inflammatory lesions in the three months prior. All participants were fully informed about the study’s goals and methods and provided consent. The study was an open, randomized, international research project. Participants were instructed to take the study drug daily before bed and refrain from using specific treatments, drugs, or cosmetics to ensure research integrity.The results inform us about long-term acne and scar treatment. ADP/BPO and BPO gels effectively treat and prevent inflammatory lesions and atrophic scarring.